Skip to main content
  • Home
  •  Shelley Zieroth

Shelley Zieroth

Director, Heart Failure and Heart Transplant Clinics

St Boniface Hospital, Winnipeg, CA

Biography

Dr Shelley Zieroth is Professor at the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, as well as Director of the Heart Failure and Heart Transplant Clinics at St Boniface Hospital in Winnipeg, Canada. She is also Head of the Medical Heart Failure Program for Cardiac Sciences Manitoba.

She is involved in several heart failure clinical trials as a PI, National Lead or Executive Committee member. She is the Past President of the Canadian Heart Failure Society and Co-Chair of the Canadian Cardiovascular Society Heart Failure Guidelines. She is co-chair of Canada’s largest annual heart failure meeting, HF Update, and Past President of the Federation of Medical Women of Canada.

Dr Shelley Zieroth is an Editorial Board member of Cardiac Failure Review.

Featured Courses

Bridging the Gap in Worsening Heart Failure: Evidence-Based Approaches to Optimising Treatment Outcomes
  • 1.25 AMA PRA Credit

Learning objectives

  • To identify high-risk patient features indicative of worsening Heart Failure (HF)
  • Name validated tools for serial prognostic assessment and risk stratification
  • Adopt the use of appropriate assessment tools during patient follow-up
  • Recall rates of recurrent HF events and their associated healthcare costs in worsening HF patients
  • Recall the clinical benefit of emerging treatments targeted to treating worsening HF
  • Initiate available treatment for the tailored management of worsening HF
See more
Hyperkalaemia in Cardiorenal Disease – A Case Based Discussion
  • Not accredited

Learning objectives

  • Explain the relationship between sub-optimal RAASi therapy and poor cardio-renal outcomes
  • Identify patients who would benefit from anti-hyperkalaemia medications
  • Select appropriate anti-hyperkalaemia treatments across a range of patient profiles
  • Adopt anti-hyperkalaemia medications as an approach to prolong optimal RAASi therapy
  • Summarise current guideline recommendations on the use of potassium binding agents
See more
Incorporating GDMT and PRO Endpoints for Personalised HF Management
  • 1.00 EBAC

Learning objectives

  • Review current GDMT in HFrEF and HFpEF
  • Describe the relationship between initiation of GDMT and HF outcomes
  • Prescribe GDMT according to current international recommendations
  • Recall the elements of the Kansas City Cardiomyopathy Questionnaire
  • Describe the clinical studies that support the use of functional and QoL measures in practice
  • Initiate quality of life and functional improvement measures in routine practice
  • Initiate SGLT-2 inhibitors in patients presenting with De novo HF and in patients already on other GDMT
  • Adopt shared decision-making with HF patients
See more